Crossmark

Recommendations by the Spanish Society of Rheumatology on risk management of biological treatment and JAK inhibitors in patients with rheumatoid arthritis

Crossref DOI link: https://doi.org/10.1016/j.reumae.2023.07.004

Published Print: 2023-12

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Balsa, Alejandro

Díaz del Campo Fontecha, Petra

Silva Fernández, Lucía

Valencia Martín, José

Nistal Martínez, Virginia

León Vázquez, Fernando

Hernández Hernández, M. Vanesa

Corominas, Héctor

Cáliz Cáliz, Rafael

Aguado García, José María

Candelas Rodríguez, Gloria

Ibargoyen Roteta, Nora

Martí Carvajal, Arturo

Plana Farras, M. Nieves

Puñal Riobóo, Janet

Park, Hye Sang

Triñanes Pego, Yolanda

Villaverde García, Virginia
Funding

Funding for this research was provided by:

Amgen

UCB
License Information

Text and Data Mining valid from 2023-12-01
More Information

This article is maintained by: Elsevier

Article Title: Recommendations by the Spanish Society of Rheumatology on risk management of biological treatment and JAK inhibitors in patients with rheumatoid arthritis

Journal Title: Reumatología Clínica (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.reumae.2023.07.004

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.reuma.2023.07.001

Content Type: article

Copyright: © 2023 Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. All rights reserved.

Document is current

Any future updates will be listed below